UPDATE : Thursday, August 22, 2019
Biopharmaceutical stocks face grim outlook in 2H by Jeong Sae-im 2019-07-17 14:11
Celltrion starts P1 trial of Xolair biosimilar by Lee Han-soo 2019-07-15 17:45
Doctors question Pexa-Vec+Imfinzi combo’s effect on colon cancer by Jeong Sae-im, Kim Yun-mi 2019-07-12 15:13
Court suspends decision on ministry’s order to revoke Invossa license by Jeong Sae-im 2019-07-12 13:11
Prosecutors raid 2 lead managers of Kolon TissueGene’s IPO by Jeong Sae-im 2019-07-11 16:39
NKMax America seeks NASDAQ listing in 2020 by Jeong Sae-im 2019-07-11 12:41
Psomagen seeks KOSDAQ listing using technology exception policy by Jeong Sae-im 2019-07-10 15:20
Kolon files administrative suit against Invossa license revocation by Jeong Sae-im 2019-07-09 11:47
SillaJen shareholders panic over exec’s selling of 160,000 stocks by Jeong Sae-im 2019-07-09 11:45
Kolon TissueGene’s ₩490 billion shares on verge of becoming worthless by Jeong Sae-im 2019-07-08 12:06
Victims question Kolon CEO’s sincerity in apology by Jeong Sae-im 2019-07-05 15:14
Samsung, Genentech settle patent dispute on Herceptin biosimilar by Lee Han-soo 2019-07-05 11:47
Kolon confident to resume US trial on Invossa by Lee Hye-seon 2019-07-04 14:05
China OKs Alteogen’s Herceptin biosimilar for clinical trials by Lee Han-soo 2019-07-04 14:04
Regulator revokes Invossa license; Kolon CEO ‘to fight in court’ by Lee Hye-seon 2019-07-03 11:52
BNO BIO to invest $1 million in Israeli biotech venture by Jeong Sae-im 2019-06-28 16:10
Shareholders in shock over HLB’s phase-3 trial setback by Jeong Sae-im 2019-06-28 10:47
‘Food and drug ministry alone can’t handle Invossa debacle’ by Jeong Sae-im 2019-06-27 12:45
Oscotech wins exception policy for continued R&D for new drugs by Jeong Sae-im 2019-06-25 14:11
Despite regulator’s ruling delay, Kolon TissueGene likely to be reviewed for delisting by Jeong Sae-im 2019-06-20 14:20
Back to Top